According to the International Agency for Research on Cancer, the incidence trends of lung cancer differs by histologic subtypes, particularly for adenocarcinoma and squamous cell carcinoma in Western countries.3 The survival of lung cancer patients has been significantly improved by EGFR inhibitors, particularly for Asian patients with lung cancer harboring specific EGFR mutations; however, most data published to date have been hospital-based or clinical trial-based and mostly on NSCLC. The gene discussed is EGFR; the disease is adenocarcinoma.